MEDIA RELEASE PR35568
Nektar to Announce Financial Results for the Second Quarter of 2009 on Tuesday, August 4,
2009, After Close of U.S.-Based Financial Markets
SAN CARLOS, Calif., Aug. 1 /PRNewswire-AsiaNet/ --
Nektar Therapeutics (Nasdaq: NKTR) will announce its financial results for the second quarter
ended June 30, 2009 on Tuesday, August 4, 2009, after the close of U.S.-based financial markets.
Howard Robin, president and chief executive officer, will host a conference call to review the results
beginning at 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT).
The press release and a live audio-only Webcast of the conference call can be accessed through a
link that is posted on the home page and Investor Relations section of the Nektar website:
Wednesday, August 19, 2009.
To access the conference call, follow these instructions:
Dial: (866) 831-6270 (U.S.); (617) 213-8858 (international)
Passcode: 25099763 (Howard Robin is the host)
An audio replay will also be available shortly following the call through Wednesday, August 19, 2009
and can be accessed by dialing (888) 286-8010 (U.S.); or (617) 801-6888 (international) with a
passcode of 26851386.
In the event that any non-GAAP financial measure is discussed on the conference call that is not
described in the press release, related information will be made available on the Investor Relations
page at the Nektar website as soon as practical after the conclusion of the conference call.
About Nektar
Nektar Therapeutics is a biopharmaceutical company developing novel therapeutics based on its
PEGylation and advanced polymer conjugation technology platforms. Nektar's technology and drug
development expertise have enabled nine approved products for partners, which include leading
biopharmaceutical companies. Nektar is also developing a robust pipeline of its own potentially high-
value therapeutics to address unmet medical needs by leveraging and expanding its technology
platforms to improve and enable molecules.
The company recently announced positive Phase 2 results for Oral NKTR-118, its proprietary novel
peripheral opioid antagonist that combines Nektar's advanced small molecule polymer conjugate
technology platform with naloxol, a derivative of the opioid-antagonist drug, naloxone. Nektar's
technology has been shown to increase oral bioavailability and inhibit penetration across the blood-
brain barrier, an important potential advance for small molecule therapies. The product is being
developed to treat opioid-induced constipation (OIC).
NKTR-102, PEGylated irinotecan, is currently in Phase 2 clinical studies in ovarian, breast and
colorectal cancer. NKTR-105, PEGylated docetaxel, is currently in a Phase 1 study in patients with
refractory solid tumors.
Nektar technology is used in nine approved partnered products in the U.S. or Europe today,
including UCB's Cimzia(R), Roche's PEGASYS(R) for hepatitis C and Amgen's Neulasta(R) for
neutropenia.
Nektar is headquartered in San Carlos, California, with additional R&D operations in Huntsville,
Alabama and Hyderabad, India.
Contacts:
Jennifer Ruddock
Nektar Therapeutics
650-631-4954
Susan Noonan
The SAN Group
212-966-3650
SOURCE: Nektar Therapeutics
CONTACT: Jennifer Ruddock of Nektar Therapeutics,
+1-650-631-4954;
or Susan Noonan of The SAN Group,
+1-212-966-3650,
for Nektar Therapeutics
(NKTR)
NEWS 
